Agios Pharma (AGIO) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Agios Pharma (AGIO) PT Raised to $90 at RBC Capital
May 7, 2018 7:39 AM EDTRBC Capital raised its price target on Agios Pharma (NASDAQ: AGIO) to $90.00 (from $88.00) while maintaining an Outperform rating.
Analsyt Kennen MacKay said came away from the R&D day more positive towards the company's internal pipeline and R&D engine. AGIO detailed the broad IDH... More
